Cytosorbents (CTSO) 10-Q6 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 05, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'csto	'
Entity Registrant Name	'Cytosorbents Corp	'
Entity Central Index Key	'0001175151	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	245,140,613

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets:	'	'
Cash and cash equivalents	$2,349,994	$1,729,344
Accounts receivable, net of allowance for doubtful accounts at $-0-	193,873	51,779
Inventories	362,542	682,372
Prepaid expenses and other current assets	737,655	476,093
Total current assets	3,644,064	2,939,588
Property and equipment - net	143,533	145,600
Other assets	251,409	254,220
Total long-term assets	394,942	399,820
Total Assets	4,039,006	3,339,408
Current Liabilities:	'	'
Accounts payable	572,014	800,670
Accrued expenses and other current liabilities	496,443	349,841
Deferred revenue	435,686	'
Convertible notes payable, net of debt discount in the amount of $281,424 at September 30, 2013 and $178,775 at December 31, 2012	1,561,576	926,225
Total current liabilities	3,065,719	2,076,736
Total liabilities	3,065,719	2,076,736
Redeemable Series B Convertible Preferred Stock, par value $0.001, 200,000 shares authorized at September 30, 2013 and December 31, 2012, respectively, 77,401.49 and 72,073.26 issued and outstanding , respectively	14,583,515	12,887,817
Stockholders' Equity (Deficit):	'	'
10% Series A Convertible Preferred Stock, par value $0.001, 12,000,000 shares authorized at September 30, 2013 and December 31, 2012, respectively; 1,716,743 and 1,594,164 shares issued and outstanding, respectively	1,717	1,594
Common Stock, par value $0.001, 800,000,000 shares authorized at September 30, 2013 and 500,000,000 shares authorized at December 31, 2012, 245,140,613 and 214,967,503 shares issued and outstanding, respectively	245,141	214,968
Additional paid-in capital	90,587,894	86,903,415
Deficit accumulated during the development stage	-104,469,233	-98,732,460
Accumulated other comprehensive loss	24,253	-12,662
Total stockholders' equity	-13,610,228	-11,625,145
Total Liabilities and Stockholders' Equity	$4,039,006	$3,339,408

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Allowance for doubtful accounts	$0	$0
Convertible notes payable current, debt discount	$281,424	$178,775
Common Stock, Par Value	$0.00	$0.00
Common Stock, shares authorized	800,000,000	500,000,000
Common Stock, shares issued	245,140,613	214,967,503
Common Stock, shares outstanding	245,140,613	214,967,503
Series B Redeemable Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, shares authorized	200,000	200,000
Preferred Stock, shares issued	77,401.49	72,073.26
Preferred Stock, shares outstanding	77,401.49	72,073.26
10% Series A Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, shares authorized	12,000,000	12,000,000
Preferred Stock, shares issued	1,716,743	1,594,164
Preferred Stock, shares outstanding	1,716,743	1,594,164

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended		200 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenue:	'	'	'	'	'
Sales	$203,561	$13,679	$507,628	$63,614	$695,280
Grant and other income	677,131	591,667	1,035,877	675,000	3,227,684
Total revenue	880,692	605,346	1,543,505	738,614	3,922,964
Cost of revenue	620,623	141,849	1,073,689	261,101	1,907,560
Gross profit	260,069	463,497	469,816	477,513	2,015,404
Other Expenses:	'	'	'	'	'
Research and development	294,198	554,266	1,706,498	1,854,407	55,635,957
Legal, financial and other consulting	157,926	150,785	570,465	385,612	9,155,600
Selling, general and administrative	687,788	359,625	1,901,768	915,402	28,312,979
Change in fair value of management and incentive units	'	'	'	'	-6,055,483
Total expenses	1,139,912	1,064,676	4,178,731	3,155,421	87,049,053
Loss from operations	-879,843	-601,179	-3,708,915	-2,677,908	-85,033,649
Other (income)/expense:	'	'	'	'	'
Gain on disposal of property and equipment	'	'	'	'	-21,663
Gain on extinguishment of debt	'	'	'	'	-216,617
Interest (income)/expense, net	84,946	50,801	299,805	447,978	7,601,355
Penalties associated with non-registration of Series A Preferred Stock	'	'	'	'	361,495
Total other (income) expense, net	84,946	50,801	299,805	447,978	7,724,570
Loss before benefit from income taxes	-964,789	-651,980	-4,008,720	-3,125,886	-92,758,219
Benefit from income taxes	'	'	'	'	-939,074
Net loss	-964,789	-651,980	-4,008,720	-3,125,886	-91,819,145
Preferred stock dividend	525,148	629,725	1,728,053	1,870,846	12,650,088
Net loss available to common shareholders	-1,489,937	-1,281,705	-5,736,773	-4,996,732	-104,469,233
Basic and diluted net loss per common share	($0.01)	($0.01)	($0.02)	($0.03)	'
Weighted average number of shares of common stock outstanding	242,512,486	204,438,894	232,426,316	193,383,650	'
Net loss	-964,789	-651,980	-4,008,720	-3,125,886	-91,819,145
Other comprehensive loss:	'	'	'	'	'
Currency translation adjustment	40,184	'	36,915	'	24,253
Comprehensive loss	($924,605)	($651,980)	($3,971,805)	($3,125,886)	($91,794,892)

CONSOLIDATED_STATEMENT_OF_CHAN

CONSOLIDATED STATEMENT OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIENCY) (USD $)	Total	Series B Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]	Preferred Stock A [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Deficit Accumulated During Development Stage [Member]
Balance at Dec. 31, 2012	($11,625,145)	$12,887,817	$214,968	$1,594	$86,903,415	($12,662)	($98,732,460)
Balance, shares at Dec. 31, 2012	'	72,073.26	214,967,503	1,594,164	'	'	'
Stock based compensation - employees, consultants and directors	300,105	'	'	'	300,105	'	'
Issuance of common stock for services rendered	65,468	'	500	'	64,968	'	'
Issuance of common stock for services rendered, shares	'	'	500,000	'	'	'	'
Issuance of Series A Preferred Stock as dividends	'	'	'	123	11,846	'	-11,969
Issuance of Series A Preferred Stock as dividends, shares	122,579	'	'	122,579	'	'	'
Issuance of Series B Preferred Stock as dividends	-1,716,084	1,716,084	'	'	'	'	-1,716,084
Issuance of Series B Preferred Stock as dividends, shares	5,526.50	5,526.50	'	'	'	'	'
Conversion of Series A and Series B into Common	20,386	-20,386	548	'	19,838	'	'
Conversion of Series A and Series B into Common (in shares)	'	-198.27	547,707	'	'	'	'
Issuance of common stock for cash	1,599,967	'	14,842	'	1,585,125	'	'
Issuance of common stock for cash, shares	'	'	14,842,328	'	'	'	'
Conversion of convertible notes to common	1,226,042	'	9,740	'	1,216,302	'	'
Conversion of convertible notes to common, shares	'	'	9,739,912	'	'	'	'
Exercise of warrants	139,527	'	3,987	'	135,540	'	'
Exercise of warrants, shares	'	'	3,986,426	'	'	'	'
Relative fair value of warrants and beneficial conversion feature in connection with issuance of convertible notes	331,117	'	'	'	331,117	'	'
Exercise of stock options	20,194	'	556	'	19,638	'	'
Exercise of stock options (in shares)	556,737	'	556,737	'	'	'	'
Other comprehensive income/(loss): foreign translation adjustment	36,915	'	'	'	'	36,915	'
Net loss	-4,008,720	'	'	'	'	'	-4,008,720
Balance at Sep. 30, 2013	($13,610,228)	$14,583,515	$245,141	$1,717	$90,587,894	$24,253	($104,469,233)
Balance, shares at Sep. 30, 2013	'	77,401.49	245,140,613	1,716,743	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		200 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities:	'	'	'
Net loss	($4,008,720)	($3,125,886)	($91,819,145)
Adjustments to reconcile net loss to net cash used by operating activities:	'	'	'
Common stock issued as inducement to convert convertible notes payable and accrued interest	'	'	3,351,961
Issuance of common stock to consultants for services	65,468	'	95,468
Depreciation and amortization	47,573	32,121	2,551,594
Amortization of debt discount	228,468	420,506	2,694,197
Gain on disposal of property and equipment	'	'	-21,663
Gain on extinguishment of debt	'	'	-216,617
Interest expense paid with Series B Preferred Stock in connection with conversion of notes payable	'	'	3,147
Abandoned patents	'	'	183,556
Bad debts - employee advances	'	'	255,882
Contributed technology expense	'	'	4,550,000
Consulting expense	'	'	237,836
Management unit expense	'	'	1,334,285
Expense for issuance of warrants	'	'	533,648
Expense for issuance of options	300,105	16,964	2,868,293
Amortization of deferred compensation	'	'	74,938
Penalties in connection with non-registration event	'	'	361,496
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-142,094	-15,863	-193,873
Inventories	319,830	-194,756	-362,542
Prepaid expenses and other current assets	318,438	-72,644	-429,203
Other assets	9,442	880	-37,511
Accounts payable and accrued expenses	38,989	84,114	3,144,793
Accrued interest expense	'	'	1,823,103
Deferred revenue	435,686	'	435,686
Net cash used by operating activities	-2,386,815	-2,854,564	-68,580,671
Cash flows from investing activities:	'	'	'
Proceeds from sale of property and equipment	'	'	32,491
Purchases of property and equipment	-33,276	'	-2,454,086
Patent costs	-18,861	-20,957	-517,375
Purchases of short-term investments	'	'	-393,607
Proceeds from sale of short-term investments	'	'	393,607
Loan receivable	'	'	-1,632,168
Net cash used by investing activities	-52,137	-20,957	-4,571,138
Cash flows from financing activities:	'	'	'
Proceeds from issuance of common stock	'	'	400,490
Proceeds from issuance of preferred stock	'	'	9,579,040
Equity contributions - net of fees incurred	1,599,967	3,050,000	51,671,278
Proceeds from borrowings	1,263,000	700,000	13,151,881
Proceeds from subscription receivables	'	'	499,395
Proceeds from exercise of stock options	20,194	'	35,940
Proceeds from exercise of warrants	139,526	'	139,526
Net cash provided by financing activities	3,022,687	3,750,000	75,477,550
Effect of exchange rates on cash	36,915	'	24,253
Net change in cash and cash equivalents	620,650	874,479	2,349,994
Cash and cash equivalents - beginning of period	1,729,344	1,186,653	'
Cash and cash equivalents - end of period	2,349,994	2,061,132	2,349,994
Supplemental disclosure of cash flow information:	'	'	'
Cash paid during the period for interest	'	'	590,189
Supplemental schedule of noncash investing and financing activities:	'	'	'
Increase in other current assets through the issuance of convertible debt	580,000	'	580,000
Debt discount in connection with issuance of convertible debt	331,117	87,700	1,975,322
Fair value of shares issued as costs of raising capital	34,034	236,565	617,520
Note payable principal and interest conversion to equity	1,226,042	685,208	13,175,491
Issuance of management units in settlement of cost of raising capital	'	'	437,206
Change in fair value of management units for cost of raising capital	'	'	278,087
Issuance of common stock in exchange for stock subscribed	'	'	399,395
Costs paid from proceeds in conjunction with issuance of preferred stock	'	'	768,063
Preferred stock dividends	1,728,053	1,870,846	12,650,088
Net effect of conversion of common stock to preferred stock prior to merger	'	'	559
Leasehold Improvements	'	'	'
Supplemental schedule of noncash investing and financing activities:	'	'	'
Issuance of member units	'	'	141,635
Loans Receivable	'	'	'
Supplemental schedule of noncash investing and financing activities:	'	'	'
Issuance of member units	'	'	1,632,168
Accounts Payable	'	'	'
Supplemental schedule of noncash investing and financing activities:	'	'	'
Issuance of member units	'	'	$1,614,446

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	9 Months Ended		200 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Series B Preferred Stock [Member]	'	'	'
Preferred Shares converted into Common shares	198.27	140.87	22,774.45
Series A Preferred Stock [Member]	'	'	'
Preferred Shares converted into Common shares	0	3,003	9,558,112
Common Stock [Member] \| Series B Preferred Stock [Member]	'	'	'
Common shares issued upon conversion	547,707	388,603	62,912,304
Common Stock [Member] \| Series A Preferred Stock [Member]	'	'	'
Common shares issued upon conversion	0	30,030	43,728,457

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Sep. 30, 2013
BASIS OF PRESENTATION [Abstract]	'
BASIS OF PRESENTATION	'

	1. BASIS OF PRESENTATION

	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q of the Securities and Exchange Commission (the "Commission") and include the results of CytoSorbents Corporation (the "Parent"), CytoSorbents, Inc., its wholly-owned operating subsidiary (the "Subsidiary"), and CytoSorbents Europe GmbH, its wholly-owned European subsidiary (the "European Subsidiary"), collectively referred to as "the Company." Accordingly, certain information and footnote disclosures required in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. Interim statements are subject to possible adjustments in connection with the annual audit of the Company's accounts for the year ended December 31, 2013. In the opinion of the Company's management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) which the Company considers necessary for the fair presentation of the Company's consolidated financial position as of September 30, 2013 and the results of its operations and cash flows for the nine and three month periods ended September 30, 2013 and 2012, and for the period January 22, 1997 (date of inception) to September 30, 2013. Results for the nine and three months ended are not necessarily indicative of results that may be expected for the entire year. The unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company and the notes thereto as of and for the year ended December 31, 2012 as included in the Company's Form 10-K filed with the Commission on April 03, 2013.

	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has experienced negative cash flows from operations since inception and has a deficit accumulated during the development stage at September 30, 2013 of $104,469,233 The Company is not currently generating significant revenue and is dependent on the proceeds of present and future financings to fund its research, development and commercialization program. These matters raise substantial doubt about the Company's ability to continue as a going concern. The Company is continuing its fund-raising efforts. Although the Company has historically been successful in raising additional capital through equity and debt financings, there can be no assurance that the Company will be successful in raising additional capital in the future or that it will be on favorable terms. We believe that we have sufficient cash to fund our operations into the second quarter of 2014, following which we will need additional funding before we can complete additional clinical studies and continue to commercialize our products. Furthermore, if the Company is successful in raising the additional financing, there can be no assurance that the amount will be sufficient to complete the Company's plans. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.

	The Company is a development stage company and has not yet generated significant revenues from inception to September 30, 2013. Since inception, the Company's expenses relate primarily to research and development, organizational activities, clinical manufacturing, regulatory compliance, sales and operational strategic planning. Although the Company has made advances on these matters, there can be no assurance that the Company will continue to be successful regarding these issues, nor can there be any assurance that the Company will successfully implement its long-term strategic plans.

	The Company has developed an intellectual property portfolio, including 32 issued U.S. patents, and multiple pending patents, covering materials, methods of production, systems incorporating the technology and multiple medical uses.

PRINCIPAL_BUSINESS_ACTIVITY_AN

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2013
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	2. PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

	Nature of Business

	The Company, through its subsidiary CytoSorbents, Inc., is engaged in the research, development and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The Company, through its European Subsidiary, has commenced initial sales and marketing related operations for the CytoSorb® device in the European Union. The Company is focused on developing this technology for multiple applications in the medical field, specifically to provide improved blood purification for the treatment of acute and chronic health complications associated with blood toxicity. In March 2011, the Company received CE Mark approval for its CytoSorb® device, and in June 2012, officially launched CytoSorb® for commercial sale in Germany and later in Austria and Switzerland with a small direct sales force. As of September 30, 2013, the Company had only limited commercial operations and, accordingly, is in the development stage. The Company has yet to generate significant revenue from product sales and has no assurance of future revenue.

	Principles of Consolidation

	The consolidated financial statements include the accounts of the Parent, CytoSorbents Corporation, and its wholly-owned subsidiaries, CytoSorbents, Inc. and CytoSorbents Europe GmbH. All significant intercompany transactions and balances have been eliminated in consolidation.

	Development Stage Corporation

	The accompanying consolidated financial statements have been prepared in accordance with the provisions of accounting and reporting by development stage enterprises.

	Cash and Cash Equivalents

	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

	Accounts Receivable

	Accounts receivable are customer obligations due under normal trade terms. The Company sells its devices to various hospitals and distributors. The Company performs ongoing credit evaluations of customers' financial condition and does not require collateral. Management reviews accounts receivable periodically to determine collectability. Balances that are determined to be uncollectible are written off to the allowance for doubtful accounts. The allowance for doubtful accounts contains a general accrual for estimated bad debts and had a balance of zero at September 30, 2013 and December 31, 2012.

	Inventories

	Inventories are valued at the lower of cost or market. At September 30, 2013 and December 31, 2012 the Company's inventory was comprised of finished goods, which amounted to approximately $211,000 and $439,000, respectively, work in process which amounted to approximately $125,000 and $195,000, respectively and raw materials, which amounted to approximately $26,000 and $49,000, respectively.

	Property and Equipment

	Property and equipment are recorded at cost less accumulated depreciation. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the lesser of their economic useful lives or the term of the related leases. Gains and losses on depreciable assets retired or sold are recognized in the statements of operations in the year of disposal. Repairs and maintenance expenditures are expensed as incurred.

	Patents

	Legal costs incurred to establish patents are capitalized. When patents are issued, capitalized costs are amortized on the straight-line method over the related patent term. In the event a patent is abandoned, the net book value of the patent is written off.

	Impairment or Disposal of Long-Lived Assets

	The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value.

	Revenue Recognition

	Product Sales: Revenues from sales of products are recognized at the time of delivery when title and risk of loss passes to the customer. Recognition of revenue also requires reasonable assurance of collection of sales proceeds and completion of all performance obligations.

	Grant Revenue: Revenue from grant income is based on contractual agreements. Certain agreements provide for reimbursement of costs, while other agreements provide for reimbursement of costs and an overhead margin. Revenues are recognized when milestones have been achieved and revenues have been earned. Costs are recorded as incurred. Costs subject to reimbursement by these grants have been reflected as costs of revenue.

	Deferred Revenue: The Company defers revenue that has been received but not yet earned on government contracts. This revenue will be recognized as income in the period in which the revenue is earned. All deferred revenue is expected to be earned within a one year of the balance sheet date.

	Research and Development

	All research and development costs and payments to laboratories and research consultants are expensed when incurred.

	Income Taxes

	Income taxes are accounted for under the asset and liability method prescribed by accounting standards for accounting for income taxes. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or the entire deferred tax asset will not be realized. Under Section 382 of the Internal Revenue Code, the net operating losses generated prior to the reverse merger may be limited due to the change in ownership. Additionally, net operating losses generated subsequent to the reverse merger may be limited in the event of changes in ownership.

	The Company follows accounting standards associated with uncertain tax positions. The Company had no unrecognized tax benefits at December 31, 2012 or 2011. The Company files tax returns in the U.S. with both federal and state jurisdictions and in other countries as required. The Company currently has no open years prior to December 31, 2010 and has no income tax related penalties or interest for the periods presented in these financial statements.

	Use of Estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends and valuation methods used in determining any debt discount associated with convertible securities.

	Concentration of Credit Risk

	The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.

As of September 30, 2013, three customers (one U.S. government grant agency, one distributor, and one direct hospital customer) accounted for approximately 73 percent of outstanding accounts receivable. At December 31, 2012, accounts receivable consisted of five direct hospital customers who in the aggregate represented 100% of outstanding accounts receivable, each of whom individually had more than 10 percent of outstanding accounts receivable. For the nine months ended September 30, 2013, approximately 67.1 percent of revenues were from two U.S. government grant agencies, and no other agency, distributor, or direct customer represented more than 10% of the Company's revenue. For the nine months ended September 30, 2012, approximately 91 percent of revenue was from two U.S. government grant agencies, each of whom individually comprised more than 10 percent of the Company's total revenue.

Financial Instruments

The carrying values of cash and cash equivalents, short-term investments, accounts payable, notes payable, and other debt obligations approximate their fair values due to their short-term nature.

Net Loss Per Common Share

Basic EPS is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period. The computation of Diluted EPS does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (See Note 6).

Stock-Based Compensation

The Company accounts for its stock-based compensation under the recognition requirements of accounting standards for accounting for stock-based compensation, for employees and directors whereby each option granted is valued at fair market value on the date of grant. Under these accounting standards, the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.

The Company also follows the guidance of accounting standards for accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants.

Effects of Recent Accounting Pronouncements

There have been no recently issued accounting standards, which would have a material impact on the Company's financial statements.

Reclassifications

Certain items for the periods ended September 30, 2012 have been reclassified to conform to the presentation at September 30, 2013. There was no change in net income as a result of these reclassifications.

CONVERTIBLE_NOTES

CONVERTIBLE NOTES	9 Months Ended
CONVERTIBLE NOTES	Sep. 30, 2013
CONVERTIBLE NOTES [Abstract]	'
CONVERTIBLE NOTES	'
	3. CONVERTIBLE NOTES

	On September 30, 2013 (the "Closing Date"), the Company issued convertible notes to certain accredited investors (the "Purchasers"), whereby the Company agreed to sell and the Purchasers agreed to purchase the convertible notes in the aggregate principal amount of $745,000 (the "Notes"). The Notes mature one (1) year from the Closing Date (the "Maturity Date"), bear interest at an annual rate of 8%, and automatically convert into shares of the Company's common stock, $0.001 par value per share (the "Common Stock"), at a conversion price of $0.10 at maturity or earlier at the option of the Purchaser. Full conversion of the principal value of the Notes would result in the issuance of 7,450,000 shares of Common Stock. In connection with the issuance of the Notes, the Company issued warrants to purchase shares of Common Stock, providing 50% coverage, exercisable at $0.125 per share (the "Warrants").

	Of the $745,000 principal amount of the Notes, $165,000 was received and is included in Cash and cash equivalents in the September 30, 2013 Consolidated Balance Sheet. The balance of $580,000 was received in early October 2013 and is included in Prepaid expenses and other current assets on the September 30, 2013 Consolidated Balance Sheet.

	On June 21, 2013 (the "Closing Date"), the Company issued convertible notes to certain accredited investors (the "Purchasers"), whereby the Company agreed to sell and the Purchasers agreed to purchase the convertible notes in the aggregate principal amount of $1,098,000 (the "Notes"). The Notes mature one (1) year from the Closing Date (the "Maturity Date"), bear interest at an annual rate of 8%, and automatically convert into shares of the Company's common stock, $0.001 par value per share (the "Common Stock"), at a conversion price of $0.125 at maturity or earlier at the option of the Purchaser. Full conversion of the principal value of the Notes would result in the issuance of 8,784,000 shares of Common Stock. In connection with the issuance of the Notes, the Company issued warrants to purchase shares of Common Stock, providing 50% coverage, exercisable at $0.15 per share (the "Warrants").

	At September 30, 2013, the Company had Convertible Notes totaling approximately $1,562,000 net of debt discount of approximately $281,000. The Notes stipulate that in the event at any time during the term of the Note, the Company closes on any debt or equity financing in an aggregate amount greater than or equal to $750,000, the noteholder will have the right to exchange the note for the equivalent dollar amount of securities sold in the new financing. The Company is not required to repay the Notes in cash, and there are no registration rights on the common stock underlying the Notes or Warrants.

	At December 31, 2012 the Company had Convertible Notes totaling $926,225 net of debt discount of $178,775 outstanding. In February 2013 all outstanding Convertible Notes plus accrued interest at 8% were converted into 9,739,912 Common Shares and debt discount was charged to interest expense.

	The Company allocates the proceeds associated with the issuance of promissory notes based on the relative fair value of the promissory notes and warrants. Additionally, the Company evaluates if the embedded conversion option results in a beneficial conversion feature by comparing the relative fair value allocated to the promissory notes to the market value of the underlying common stock subject to conversion. In connections with the promissory note issuances during the periods ended September 30, 2013 and 2012 the Company received proceeds of $1,843,000 and $700,000, respectively. The Company allocated the proceeds in accordance with FASB Codification Topic 470 based on the related fair value as follows for the $1,843,000: $1,511,883 was allocated to the promissory notes and $171,012 to the warrants. Additionally, the embedded conversion feature resulted in a beneficial conversion feature in the amount of $160,105. For the $700,000, $612,300 was allocated to the promissory notes and $38,788 to the warrants. Additionally, the embedded conversion feature resulted in a beneficial conversion feature in the amount of $48,912. The value assigned to the warrants resulting from the relative fair value calculation as well as the value of the beneficial conversion feature is recorded as a debt discount and is presented in the consolidated balance sheets. The debt discount is being amortized to interest expense over the term of the promissory notes. During the nine months ended September 30, 2012 Convertible Notes in the principal and accrued interest amount of $685,208 were converted into 6,852,088 Common shares resulting in a reduction of debt discount and charge to interest expense in the amount of $235,762.

STOCKHOLDERS_EQUITY_DEFICIT

STOCKHOLDERS' EQUITY (DEFICIT)	9 Months Ended
STOCKHOLDERS' EQUITY (DEFICIT)	Sep. 30, 2013
STOCKHOLDERS' EQUITY (DEFICIT) [Abstract]	'
STOCKHOLDERS' EQUITY	'
	4. STOCKHOLDERS' EQUITY (DEFICIT)

	During the nine months ended September 30, 2013, the Company recorded non-cash stock dividends totaling approximately $1,728,000 in connection with the issuance of 5,526.50 shares of Series B Preferred Stock and 122,579 shares of Series A Preferred Stock.

	During the nine months ended September 30, 2013, the Company incurred stock-based compensation expense due to the issuance of stock options, and amortization of unvested stock options. The aggregate expense for the nine months ended September 30, 2013 is approximately $300,000.

	The summary of the stock option activity for the nine months ended September 30, 2013 is as follows:
							Weighted
							Average		Weighted
							Exercise		Average
							Price		Remaining
			Shares				per Share		Life (Years)

	Outstanding, January 1, 2013			36,667,616			$	0.23		6.1
	Granted			13,985,000			$	0.11		5.8
	Cancelled			(2,235,000	)		$	0.12		-
	Exercised			(556,737	)		$	0.04		-
	Expired			(9,402	)		$	2.01		-
	Outstanding September 30, 2013			47,851,477			$	0.21		5.4

	The fair value of each stock option was estimated using the Black Scholes pricing model which takes into account as of the grant date the exercise price (ranging from $0.106 to $0.129 per share) and expected life of the stock option ( ranging from 5-10 years), the current price of the underlying stock and its expected volatility (approximately 28 percent), expected dividends (zero percent) on the stock and the risk free interest rate (0.8 to 1.9 percent) for the term of the stock option.
	At September 30, 2013, the aggregate intrinsic value of options outstanding and currently exercisable amounted to approximately $842,000.

	The summary of the status of the Company's non-vested options for the nine months ended September 30, 2013 is as follows:
							Weighted
							Average
							Grant
							Date
			Shares				Fair Value

	Non-vested, January 1, 2013			7,394,000			$	0.05
	Granted			13,985,000			$	0.03
	Cancelled			(2,035,000	)		$	0.06
	Vested			(5,926,000	)		$	0.05

	Non-vested, September 30, 2013			13,418,000			$	0.03

	As of September 30, 2013, approximately $104,000 of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted average period of 1.55 years. On April 3, 2013, the Company's Board of Directors approved a 2013 Stock Option Grant totaling 10,305,000 options, available in part to all eligible employees of the Company, that vests only with the achievement of certain pre-determined milestones relating to commercialization of CytoSorb®, financing, business development, and product development. Due to the uncertainty over whether approximately 9,455,000 of the 10,305,000 options granted will vest, no charge for these options has been recorded in the consolidated statements of operations for the nine months ended September 30, 2013. The grant date fair value of these unvested options amounts to approximately $284,000. The Company will evaluate on an ongoing basis the probability and likelihood of any of these performance milestones being achieved and will accrue charges as it becomes likely that they will be achieved.

	In addition, a pool of 22,750,000 shares of restricted stock was allocated, but not awarded, to only be awarded with the achievement of certain long-term milestones. Should these long-term milestones not be met in 2013, these restricted shares would be cancelled.

	As of September 30, 2013, the Company has the following warrants to purchase common stock outstanding:

	Number of Shares		Warrant				Warrant
	To be Purchased		Exercise				Expiration
			Price per Share				Date


	397,825		$	0.04			30-Sep-14
	1,750,000		$	0.1			16-Aug-15
	1,600,000		$	0.13			16-Aug-15
	1,333,333		$	0.15			16-Aug-15
	490,000		$	0.1			22-Oct-15
	196,000		$	0.13			22-Oct-15
	163,333		$	0.15			22-Oct-15
	625,000		$	0.1			2-Nov-15
	250,000		$	0.13			2-Nov-15
	208,334		$	0.15			2-Nov-15
	500,000		$	0.1			19-Nov-15
	200,000		$	0.13			19-Nov-15
	166,667		$	0.15			19-Nov-15
	5,000,000		$	0.1			15-Feb-16
	2,200,000		$	0.13			15-Feb-16
1,833,333		$	0.15			15-Feb-16
240,125		$	1.25			24-Oct-16
1,166,667		$	0.18			10-Feb-17
4,392,000		$	0.15			21-Jun-18
3,725,000		$	0.12			30-Sep-18
26,437,617

During the first quarter of 2013, Convertible Notes in the principal and accrued interest amount of $1,226,042 were converted into 9,739,912 Common shares.

In December 2011, the Company terminated the original Purchase Agreement with Lincoln Park Capital Fund, LLC ("LPC") and executed a new purchase agreement, or the New Purchase Agreement, and a registration rights agreement, or the New Registration Rights Agreement, with LPC. Under the New Purchase Agreement, LPC is obligated, under certain conditions, to purchase from the Company up to $8.5 million of our Common Stock, from time to time over a thirty-two (32) month period.

The Company has the right, but not the obligation, to direct LPC to purchase up to $8,500,000 of its Common Stock in amounts up to $50,000 as often as every two business days under certain conditions. The Company can also accelerate the amount of its common stock to be purchased under certain circumstances. No sales of shares may occur at a purchase price below $0.10 per share or without a registration statement having been declared effective. The purchase price of the shares will be based on the market prices of our shares at the time of sale as computed under the New Purchase Agreement without any fixed discount. The Company may at any time at its sole discretion terminate the New Purchase Agreement without fee, penalty or cost upon one business days' notice.

There was no up-front commitment fee paid to LPC for entering into the new agreement. In the event the Company directs LPC to purchase up to $8,500,000 of its Common Stock, the Company is obligated to issue up to an additional 1,634,615 commitment fee shares of Common Stock on a pro rata basis. LPC may not assign any of its rights or obligations under the Purchase Agreement.

During the nine months ended September 30, 2013 the Company received approximately $1,600,000 as proceeds from the sale of approximately 14,529,000 shares of Common Stock per the terms of the Purchase Agreement with LPC at an average price of approximately $0.110 per share of Common. Per the terms of the Purchase Agreement the Company also issued an additional approximately 308,000 shares of Common Stock as additional Commitment Fee shares. The fair value of the Commitment shares of approximately $34,000 has been recorded as a cost of raising capital.

As of September 30, 2013, $3,400,000 remained available under the Purchase Agreement with LPC. The Purchase Agreement terminates in August 2014.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2013
COMMITMENTS AND CONTINGENCIES [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	5. COMMITMENTS AND CONTINGENCIES

	Employment Agreements

	The Company is currently in the process of renewing employment agreements with its Chief Executive Officer and its Chief Operating Officer.

	On May 7, 2013, the Company entered into an employment agreement with Kathleen P. Bloch to become the Company's Chief Financial Officer. Ms. Bloch's employment agreement states that she will perform the services and duties that are normally and customarily associated with this position as well as other associated duties as our Board reasonably determines. The agreement commences on May 29, 2013 and expires on May 31, 2014 and calls for an initial base salary of $200,000 payable in equal semi-monthly installments in accordance with the Company's usual practice. As a signing bonus, Ms. Bloch was also given a ten-year option to purchase 1,000,000 shares of the Company's common stock at an exercise price of $0.116 per share. This option vests in equal installments over the next two years: 500,000 options at the 12 month anniversary, and 500,000 options at 24 month anniversary of the signing of this employment agreement, provided that Ms. Bloch remains a full-time employee of the Company.

	Litigation

	The Company is currently not involved, but may at times be involved in various claims and legal actions.

	Royalty Agreements

	Pursuant to an agreement dated August 11, 2003, an existing investor agreed to make a $4 million equity investment in the Company. These amounts were received by the Company in 2003. In connection with this agreement, the Company granted the investor a future royalty of 3% on all gross revenues received by the Company from the sale of its CytoSorb® device. For the nine months ended September 30, 2013 the Company has recorded royalty costs of approximately $15,000.

	License Agreements

	In an agreement dated September 1, 2006, the Company entered into a license agreement which provides the Company the exclusive right to use its patented technology and proprietary know how relating to adsorbent polymers for a period of 18 years. Under the terms of the agreement, the Company has agreed to pay royalties of 2.5% to 5% on the sale of certain of its products if and when those products are sold commercially for a term not greater than 18 years commencing with the first sale of such product. For the nine months ended September 30, 2013 per the terms of the license agreement the Company has recorded royalty costs of approximately $13,000.

	Warrant Agreement

	As inducement to invest additional funds in the private placement of Series B Preferred Stock, additional consideration was granted to the participants of the Series B Preferred Stock offering in the event that litigation is commenced against CytoSorbents prior to June 30, 2018, claiming patent infringement on certain of the Company's issued patents. In the event this litigation arises the Company may be required to issue warrants to purchase in the aggregate up to a maximum of ten million shares of Common Stock subject to certain adjustments. Through September 30, 2013 no such litigation has arisen and due to the deemed low probability of this potential outcome; the Company has not booked a contingent liability for this agreement.

NET_LOSS_PER_SHARE

NET LOSS PER SHARE	9 Months Ended
NET LOSS PER SHARE	Sep. 30, 2013
NET LOSS PER SHARE [Abstract]	'
NET LOSS PER SHARE	'
	6. NET LOSS PER SHARE

	Basic loss per share and diluted loss per share for the nine months ended September 30, 2013 and 2012 have been computed by dividing the net loss for each respective period by the weighted average number of shares outstanding during that period.

	All outstanding warrants and options representing approximately 74,289,000 and 63,970,000 incremental shares at September 30, 2013 and 2012, respectively, as well as shares issuable upon conversion of Series A and Series B Preferred Stock representing approximately 215,310,000 and 195,595,000 incremental shares at September 30, 2013 and 2012, respectively, as well as potential shares issuable upon Note conversion into Common Stock representing approximately 16,234,000 and 12,030,000 incremental shares at September 30, 2013 and 2012, respectively, have been excluded from the computation of diluted loss per share as they are anti-dilutive.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2013
SUBSEQUENT EVENTS [Abstract]	'
SUBSEQUENT EVENTS	'
	7. SUBSEQUENT EVENTS

	The Company has evaluated subsequent events occurring after the balance sheet date through the date of the issuance of this report and has determined that there are no material subsequent events requiring disclosure in these financial statements.

PRINCIPAL_BUSINESS_ACTIVITY_AN1

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2013
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Nature of Business	'
	Nature of Business

	The Company, through its subsidiary CytoSorbents, Inc., is engaged in the research, development and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The Company, through its European Subsidiary, has commenced initial sales and marketing related operations for the CytoSorb® device in the European Union. The Company is focused on developing this technology for multiple applications in the medical field, specifically to provide improved blood purification for the treatment of acute and chronic health complications associated with blood toxicity. In March 2011, the Company received CE Mark approval for its CytoSorb® device, and in June 2012, officially launched CytoSorb® for commercial sale in Germany and later in Austria and Switzerland with a small direct sales force. As of September 30, 2013, the Company had only limited commercial operations and, accordingly, is in the development stage. The Company has yet to generate significant revenue from product sales and has no assurance of future revenue.

Principles of Consolidation	'
	Principles of Consolidation

	The consolidated financial statements include the accounts of the Parent, CytoSorbents Corporation, and its wholly-owned subsidiaries, CytoSorbents, Inc. and CytoSorbents Europe GmbH. All significant intercompany transactions and balances have been eliminated in consolidation.

Development Stage Corporation	'
	Development Stage Corporation

	The accompanying consolidated financial statements have been prepared in accordance with the provisions of accounting and reporting by development stage enterprises.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents

	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Accounts Receivable	'
	Accounts Receivable

	Accounts receivable are customer obligations due under normal trade terms. The Company sells its devices to various hospitals and distributors. The Company performs ongoing credit evaluations of customers' financial condition and does not require collateral. Management reviews accounts receivable periodically to determine collectability. Balances that are determined to be uncollectible are written off to the allowance for doubtful accounts. The allowance for doubtful accounts contains a general accrual for estimated bad debts and had a balance of zero at September 30, 2013 and December 31, 2012.

Inventories	'

	Inventories

	Inventories are valued at the lower of cost or market. At September 30, 2013 and December 31, 2012 the Company's inventory was comprised of finished goods, which amounted to approximately $211,000 and $439,000, respectively, work in process which amounted to approximately $125,000 and $195,000, respectively and raw materials, which amounted to approximately $26,000 and $49,000, respectively.

Property and Equipment	'
	Property and Equipment

	Property and equipment are recorded at cost less accumulated depreciation. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the lesser of their economic useful lives or the term of the related leases. Gains and losses on depreciable assets retired or sold are recognized in the statements of operations in the year of disposal. Repairs and maintenance expenditures are expensed as incurred.

Patents	'
	Patents

	Legal costs incurred to establish patents are capitalized. When patents are issued, capitalized costs are amortized on the straight-line method over the related patent term. In the event a patent is abandoned, the net book value of the patent is written off.

Impairment or Disposal of Long-Lived Assets	'
	Impairment or Disposal of Long-Lived Assets

	The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value.

Revenue Recognition	'
	Revenue Recognition

	Product Sales: Revenues from sales of products are recognized at the time of delivery when title and risk of loss passes to the customer. Recognition of revenue also requires reasonable assurance of collection of sales proceeds and completion of all performance obligations.

	Grant Revenue: Revenue from grant income is based on contractual agreements. Certain agreements provide for reimbursement of costs, while other agreements provide for reimbursement of costs and an overhead margin. Revenues are recognized when milestones have been achieved and revenues have been earned. Costs are recorded as incurred. Costs subject to reimbursement by these grants have been reflected as costs of revenue.

	Deferred Revenue: The Company defers revenue that has been received but not yet earned on government contracts. This revenue will be recognized as income in the period in which the revenue is earned. All deferred revenue is expected to be earned within a one year of the balance sheet date.

Research and Development	'

	Research and Development

	All research and development costs and payments to laboratories and research consultants are expensed when incurred.

Income Taxes	'
	Income Taxes

	Income taxes are accounted for under the asset and liability method prescribed by accounting standards for accounting for income taxes. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or the entire deferred tax asset will not be realized. Under Section 382 of the Internal Revenue Code, the net operating losses generated prior to the reverse merger may be limited due to the change in ownership. Additionally, net operating losses generated subsequent to the reverse merger may be limited in the event of changes in ownership.

	The Company follows accounting standards associated with uncertain tax positions. The Company had no unrecognized tax benefits at December 31, 2012 or 2011. The Company files tax returns in the U.S. with both federal and state jurisdictions and in other countries as required. The Company currently has no open years prior to December 31, 2010 and has no income tax related penalties or interest for the periods presented in these financial statements.

Use of Estimates	'

	Use of Estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends and valuation methods used in determining any debt discount associated with convertible securities.

Concentration of Credit Risk	'
	Concentration of Credit Risk

	The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.

	As of September 30, 2013, three customers (one U.S. government grant agency, one distributor, and one direct hospital customer) accounted for approximately 73 percent of outstanding accounts receivable. At December 31, 2012, accounts receivable consisted of five direct hospital customers who in the aggregate represented 100% of outstanding accounts receivable, each of whom individually had more than 10 percent of outstanding accounts receivable. For the nine months ended September 30, 2013, approximately 67.1 percent of revenues were from two U.S. government grant agencies, and no other agency, distributor, or direct customer represented more than 10% of the Company's revenue. For the nine months ended September 30, 2012, approximately 91 percent of revenue was from two U.S. government grant agencies, each of whom individually comprised more than 10 percent of the Company's total revenue.

Financial Instruments	'
	Financial Instruments

	The carrying values of cash and cash equivalents, short-term investments, accounts payable, notes payable, and other debt obligations approximate their fair values due to their short-term nature.

Net Loss Per Common Share	'
	Net Loss Per Common Share

	Basic EPS is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period. The computation of Diluted EPS does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (See Note 6).
Stock-Based Compensation	'
	Stock-Based Compensation

	The Company accounts for its stock-based compensation under the recognition requirements of accounting standards for accounting for stock-based compensation, for employees and directors whereby each option granted is valued at fair market value on the date of grant. Under these accounting standards, the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.

	The Company also follows the guidance of accounting standards for accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants.

Effects of Recent Accounting Pronouncements	'
	Effects of Recent Accounting Pronouncements

	There have been no recently issued accounting standards, which would have a material impact on the Company's financial statements.

Reclassifications	'

	Reclassifications

	Certain items for the periods ended September 30, 2012 have been reclassified to conform to the presentation at September 30, 2013. There was no change in net income as a result of these reclassifications.

STOCKHOLDERS_EQUITY_DEFICIT_Ta

STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	9 Months Ended
STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	Sep. 30, 2013
STOCKHOLDERS' EQUITY (DEFICIT) [Abstract]	'
Summary of Stock Option Activity	'

	The summary of the stock option activity for the nine months ended September 30, 2013 is as follows:
					Weighted
					Average		Weighted
					Exercise		Average
					Price		Remaining
		Shares			per Share		Life (Years)

	Outstanding, January 1, 2013		36,667,616		$	0.23		6.1
	Granted		13,985,000		$	0.11		5.8
	Cancelled		(2,235,000	)	$	0.12		-
	Exercised		(556,737	)	$	0.04		-
	Expired		(9,402	)	$	2.01		-
	Outstanding September 30, 2013		47,851,477		$	0.21		5.4

Summary of Status of Non-Vested Options	'
	The summary of the status of the Company's non-vested options for the nine months ended September 30, 2013 is as follows:
					Weighted
					Average
					Grant
					Date
		Shares			Fair Value

	Non-vested, January 1, 2013		7,394,000		$	0.05
	Granted		13,985,000		$	0.03
	Cancelled		(2,035,000	)	$	0.06
	Vested		(5,926,000	)	$	0.05

	Non-vested, September 30, 2013		13,418,000		$	0.03

Warrants to Purchase Common Stock	'
	As of September 30, 2013, the Company has the following warrants to purchase common stock outstanding:

	Number of Shares	Warrant			Warrant
	To be Purchased	Exercise			Expiration
		Price per Share			Date


	397,825	$	0.04		30-Sep-14
	1,750,000	$	0.1		16-Aug-15
	1,600,000	$	0.13		16-Aug-15
	1,333,333	$	0.15		16-Aug-15
	490,000	$	0.1		22-Oct-15
	196,000	$	0.13		22-Oct-15
	163,333	$	0.15		22-Oct-15
	625,000	$	0.1		2-Nov-15
	250,000	$	0.13		2-Nov-15
	208,334	$	0.15		2-Nov-15
	500,000	$	0.1		19-Nov-15
	200,000	$	0.13		19-Nov-15
	166,667	$	0.15		19-Nov-15
	5,000,000	$	0.1		15-Feb-16
	2,200,000	$	0.13		15-Feb-16
	1,833,333	$	0.15		15-Feb-16
	240,125	$	1.25		24-Oct-16
	1,166,667	$	0.18		10-Feb-17
	4,392,000	$	0.15		21-Jun-18
	3,725,000	$	0.12		30-Sep-18
	26,437,617

BASIS_OF_PRESENTATION_Details

BASIS OF PRESENTATION (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
BASIS OF PRESENTATION [Abstract]	'	'
Deficit accumulated during the development stage	$104,469,233	$98,732,460
Number of patents issued	32	'

PRINCIPAL_BUSINESS_ACTIVITY_AN2

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012
	Sep. 30, 2013	Dec. 31, 2012	Accounts receivable [Member]	Revenue [Member]	Revenue [Member]
Concentration Risk [Line Items]	'	'	'	'	'
Inventory of finished goods	$211,000	$439,000	'	'	'
Inventory of work in progress	125,000	195,000	'	'	'
Inventory of raw materials	26,000	49,000	'	'	'
Accounts receivable, allowance for doubtful accounts	$0	$0	'	'	'
Concentration risk percentage	'	'	73.00%	67.10%	91.00%

CONVERTIBLE_NOTES_Details

CONVERTIBLE NOTES (Details) (USD $)	1 Months Ended		9 Months Ended		24 Months Ended	200 Months Ended
CONVERTIBLE NOTES (Details) (USD $)	Jun. 21, 2013	Feb. 28, 2013	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 21, 1997
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Promissory notes, aggregate principal amount	$1,098,000	'	$745,000	$685,208	'	$745,000	'	'	'
Promissory note, maturity period	'1 year	'	'1 year	'	'	'	'	'	'
Promissory note, convertible, conversion price per share	$0.13	'	$0.13	'	'	$0.13	'	'	'
Percentage of principal amount used to calculate shares of common stock for warrant coverage	'	'	50.00%	'	'	50.00%	'	'	'
Exercise price of warrant	$0.15	'	$0.10	'	'	'	'	'	'
Fair value of convertible notes	'	'	1,511,883	612,300	'	1,511,883	'	'	'
Fair value of warrants	'	'	171,012	38,788	'	171,012	'	'	'
Debt instrument, beneficial conversion feature	'	'	160,105	48,912	'	'	'	'	'
Convertible notes payable	'	'	1,562,000	'	'	1,562,000	926,225	'	'
Debt discount to be amortized	'	'	281,000	'	'	281,000	178,775	'	'
Interest rate	8.00%	8.00%	8.00%	'	8.00%	'	'	'	'
Common shares issued in exchange for convertible notes	8,784,000	9,739,912	7,450,000	6,852,088	'	'	'	'	'
Interest expense	'	'	0	235,762	'	'	'	'	'
Common Stock, Par Value	'	'	$0.00	'	'	$0.00	$0.00	'	'
Proceeds from borrowings	'	'	1,263,000	700,000	'	13,151,881	'	'	'
Prepaid expenses and other current assets	'	'	737,655	'	'	737,655	476,093	'	'
Cash and cash equivalents	'	'	2,349,994	2,061,132	'	2,349,994	1,729,344	1,186,653	'
Minimum [Member]	'	'	'	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Aggregate closing rate of debt or equity financing	'	'	750,000	'	'	'	'	'	'
Purchasers Note [Member]	'	'	'	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Prepaid expenses and other current assets	'	'	580,000	'	'	580,000	'	'	'
Cash and cash equivalents	'	'	$165,000	'	'	$165,000	'	'	'

STOCKHOLDERS_EQUITY_DEFICIT_Na

STOCKHOLDERS' EQUITY (DEFICIT) (Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

200 Months Ended

9 Months Ended

200 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

2013 Stock Option Plan [Member]

Maximum [Member]

Minimum [Member]

Common Stock [Member]

Lincoln Park Capital Fund, LLC [Member]

10% Series A Preferred Stock [Member]

Additional Commitment Fee [Member]

Stockholders Equity [Line Items]

Preferred Stock, shares authorized

12,000,000

Issuance of Series B Preferred Stock as dividends, shares

5,526.50

Issuance of Series A Preferred Stock as dividends, shares

122,579

Preferred stock dividend

$525,148

$629,725

$1,728,053

$1,870,846

$12,650,088

Preferred stock, par value

$0.00

Number of preferred shares converted

3,003

9,558,112

Exercise price

$0.13

$0.11

Expected life

'10 years

'5 years

Expected volatility rate

28.00%

Expected dividends

0.00%

Risk free interest rate, minimum

0.80%

Risk free interest rate, maximum

1.90%

Aggregate intrinsic value of options outstanding and exercisable

842,000

Unrecognized compensation cost related to stock option

104,000

Unrecognized compensation costs related to stock options weighted average period of recognition

'1 year 6 months 18 days

Non-vested options expected to vest

10,305,000

Grant date fair value of these unvested options

284,000

Conversion of convertible notes to common share

1,226,042

685,208

13,175,491

Number of common stock issued in exchange for convertible notes

9,739,912

Purchase agreement, amount of shares

8,500,000

1,634,615

Period for purchase of common stock under agreement

'32 months

Amount of shares that can be sold as often as every two business days

50,000

Issuance price of common stock per share

$0.10

$0.11

Number of business days in which up to $50,000 amount of stock can be sold

'2 days

Issuance of common stock for cash, shares

14,842,328

Proceeds from issuance of common stock

400,490

1,600,000

Common stock shares to be issued

1,429,000

Issuance of common stock for services rendered, shares

500,000

Fair value of stock issued as commitment fee

34,000

Number of shares to be purchased

26,437,617

Stock-based compensation expense

300,000

Additional shares issued

308,000

Remaining value under purchase agreement

$3,400,000

Option to purchase

22,750,000

STOCKHOLDERS_EQUITY_DEFICIT_Su

STOCKHOLDERS' EQUITY (DEFICIT) (Summary of Stock Option Activity) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Shares	'
Outstanding, beginning balance	36,667,616
Granted	13,985,000
Cancelled	-2,235,000
Exercised	-556,737
Expired	-9,402
Outstanding, ending balance	47,851,477
Weighted Average Exercise Price per Share	'
Outstanding, beginning balance	$0.23
Granted	$0.11
Cancelled	$0.12
Exercised	$0.04
Expired	$2.01
Outstanding, ending balance	$0.21
Weighted Average Remaining Contractual Life (Years)	'
Outstanding, beginning balance	'6 years 1 month 6 days
Granted	'5 years 9 months 18 days
Outstanding, ending balance	'5 years 4 months 24 days

STOCKHOLDERS_EQUITY_DEFICIT_Su1

STOCKHOLDERS' EQUITY (DEFICIT) (Summary of Status of Non-Vested Options) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Shares	'
Non-vested, beginning balance	7,394,000
Granted	13,985,000
Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeitures In Period	-2,035,000
Vested	-5,926,000
Non-vested, ending balance	13,418,000
Weighted Average Grant Date Fair Value	'
Non-vested, beginning balance	$0.05
Granted	$0.03
Cancelled	$0.06
Vested	$0.05
Non-vested, ending balance	$0.03

STOCKHOLDERS_EQUITY_DEFICIT_Wa

STOCKHOLDERS' EQUITY (DEFICIT) (Warrants to Purchase Common Stock) (Details)	Sep. 30, 2013
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	26,437,617
Warrant 1	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	3,986,429
Warrant Exercise Price per Share	0.04
Warrant Expiration Date	'July 25, 2013
Warrant 2	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	397,825
Warrant Exercise Price per Share	0.04
Warrant Expiration Date	'September 30, 2014
Warrant 3	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	1,750,000
Warrant Exercise Price per Share	0.1
Warrant Expiration Date	'August 16, 2015
Warrant 4	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	1,600,000
Warrant Exercise Price per Share	0.13
Warrant Expiration Date	'August 16, 2015
Warrant 5	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	1,333,333
Warrant Exercise Price per Share	0.15
Warrant Expiration Date	'August 16, 2015
Warrant 6	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	490,000
Warrant Exercise Price per Share	0.1
Warrant Expiration Date	'October 22, 2015
Warrant 7	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	196,000
Warrant Exercise Price per Share	0.13
Warrant Expiration Date	'October 22, 2015
Warrant 8	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	163,333
Warrant Exercise Price per Share	0.15
Warrant Expiration Date	'October 22, 2015
Warrant 9	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	625,000
Warrant Exercise Price per Share	0.1
Warrant Expiration Date	'November 2, 2015
Warrant 10	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	250,000
Warrant Exercise Price per Share	0.13
Warrant Expiration Date	'November 2, 2015
Warrant 11	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	208,334
Warrant Exercise Price per Share	0.15
Warrant Expiration Date	'November 2, 2015
Warrant 12	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	500,000
Warrant Exercise Price per Share	0.1
Warrant Expiration Date	'November 19, 2015
Warrant 13	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	200,000
Warrant Exercise Price per Share	0.13
Warrant Expiration Date	'November 19, 2015
Warrant 14	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	166,667
Warrant Exercise Price per Share	0.15
Warrant Expiration Date	'November 19, 2015
Warrant 15	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	5,000,000
Warrant Exercise Price per Share	0.1
Warrant Expiration Date	'February 15, 2016
Warrant 16	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	2,200,000
Warrant Exercise Price per Share	0.13
Warrant Expiration Date	'February 15, 2016
Warrant 17	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	1,833,333
Warrant Exercise Price per Share	0.15
Warrant Expiration Date	'February 15, 2016
Warrant 18	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	240,125
Warrant Exercise Price per Share	1.25
Warrant Expiration Date	'October 24, 2016
Warrant 19	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	1,166,667
Warrant Exercise Price per Share	0.18
Warrant Expiration Date	'February 10, 2017
Warrant 20	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	4,392,000
Warrant Exercise Price per Share	0.15
Warrant Expiration Date	'June 21, 2018
Warrant 21	'
Stockholders Equity [Line Items]	'
Number of Shares To be Purchased	3,725,000
Warrant Exercise Price per Share	0.12
Warrant Expiration Date	'September 30, 2018

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) (USD $)	Sep. 30, 2013	7-May-13	Sep. 30, 2013	7-May-13	7-May-13	Aug. 11, 2003	Sep. 30, 2013	Sep. 01, 2006	Sep. 30, 2013
		Chief Financial Officer [Member]	Chief Financial Officer [Member]	Chief Financial Officer [Member]	Chief Financial Officer [Member]	Royalty Agreements [Member]	Royalty Agreements [Member]	License Agreement [Member]	License Agreement [Member]
				Installment One [Member]	Installment Two [Member]
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'	'	'	'
Equity investment by an existing investor	'	'	'	'	'	$4,000,000	'	'	'
Future royalty payment percentage on gross gross revenue	'	'	'	'	'	3.00%	'	'	'
Royalty cost	'	'	'	'	'	'	15,000	'	13,000
Term of License Agreement	'	'	'	'	'	'	'	'18 years	'
Royalty rate, lower limit	'	'	'	'	'	'	'	2.50%	'
Royalty rate, upper limit	'	'	'	'	'	'	'	5.00%	'
Salary	'	$200,000	'	'	'	'	'	'	'
Exercise price	'	'	$0.12	'	'	'	'	'	'
Option to purchase	22,750,000	1,000,000	'	500,000	500,000	'	'	'	'

NET_LOSS_PER_SHARE_Details

NET LOSS PER SHARE (Details)	9 Months Ended
NET LOSS PER SHARE (Details)	Sep. 30, 2013	Sep. 30, 2012
Stock Options and Warrants [Member]	'	'
Earnings Per Share Basic [Line Items]	'	'
Number of shares excluded from the calculation of diluted loss per share	74,289,000	63,790,000
Convertible Series A and Series B Preferred Stock [Member]	'	'
Earnings Per Share Basic [Line Items]	'	'
Number of shares excluded from the calculation of diluted loss per share	215,310,000	195,595,000
Convertible Notes [Member]	'	'
Earnings Per Share Basic [Line Items]	'	'
Number of shares excluded from the calculation of diluted loss per share	16,234,000	12,030,000

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	9 Months Ended		200 Months Ended
SUBSEQUENT EVENTS (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Subsequent Event [Line Items]	'	'	'
Issuance price of common stock per share	$0.10	'	'
Proceeds from issuance of common stock	'	'	$400,490
Exercise of stock options	$20,194	'	'
Restricted stock allocated	22,750,000	'	22,750,000